70%Confidence
0Views
FDASource
2026-03-28Date
Summary
Harvard Drug Group's packaging defect for Midodrine tablets reveals potential supply chain vulnerabilities in blister packaging operations, which could affect patient safety and medication efficacy. This may prompt increased scrutiny of packaging processes across the generic pharmaceutical industry.
Actionable: Healthcare providers should check their midodrine tablet inventories and verify packaging integrity before dispensing.
AI Confidence: 70%
Data Points
firmThe Harvard Drug Group LLC
classificationClass II
statusOngoing
distributionNationwide US.
productMidodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs), Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapol
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now